The effect of mesenchymal stem cells on dynamic changes of T cell subsets in experimental autoimmune uveoretinitis

Clinical and Experimental Immunology

Volumn 173, Issue 1, 2013, Pages 28-37

  Li, G ^a,c   Yuan, L ^a,d   Ren, X ^a   Nian, H ^a   Zhang, L ^b   Han, Z C ^b   Li, X ^a   Zhang, X ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^c LIAOCHENG PEOPLE'S HOSPITAL   (China)

^d Xingtai Eye Hospital   (China)

Author keywords

Experimental autoimmune uveoretinitis; Mesenchymal stem cells; Treg; Th1; Th17

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; UVEORETINITIS;

ANIMALS; AQUEOUS HUMOR; LYMPHOKINES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NERVOUS SYSTEM AUTOIMMUNE DISEASE, EXPERIMENTAL; ORGAN SPECIFICITY; RATS; RATS, INBRED LEW; RATS, WISTAR; RETINITIS; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; TH1 CELLS; TH17 CELLS; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA1; UVEITIS;

EID: 84878794983     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12080     Document Type: Article

References (35)

1. Servat JJ, Mears KA, Black EH, Huang JJ. Biological agents for the treatment of uveitis. Exp Opin Biol Ther 2012; 12:311-328.
2. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant 2011; 20:5-14.
3. Zhang X, Jiao C, Zhao S. Role of mesenchymal stem cells in immunological rejection of organ transplantation. Stem Cell Rev 2009; 5:402-409.
4. De Miguel MP, Fuentes-Julian S, Blazquez-Martinez A etal. Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr Mol Med 2012; 12:574-591.
5. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol 2012; 67:1-8.
6. Sun L, Wang D, Liang J etal. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010; 62:2467-2475.
7. Ciccocioppo R, Bernardo ME, Sgarella A etal. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60:788-798.
8. Darlington PJ, Boivin MN, Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Exp Rev Neurother 2011; 11:1295-1303.
9. Liu Y, Mu R, Wang S etal. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010; 12:R210.
10. Xu J, Wang D, Liu D etal. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren's syndrome. Blood 2012; 120:3142-3151.
11. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2:34.
12. Svobodova E, Krulova M, Zajicova A etal. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev 2012; 21:901-910.
13. Mei SH, Haitsma JJ, Dos Santos CC etal. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010; 182:1047-1057.
14. Maltman DJ, Hardy SA, Przyborski SA. Role of mesenchymal stem cells in neurogenesis and nervous system repair. Neurochem Int 2011; 59:347-356.
15. Zhang X, Ren X, Li G etal. Mesenchymal stem cells ameliorate experimental autoimmune uveoretinitis by comprehensive modulation of systemic autoimmunity. Invest Ophthalmol Vis Sci 2011; 52:3143-3152.
16. Tasso R, Ilengo C, Quarto R, Cancedda R, Caspi RR, Pennesi G. Mesenchymal stem cells induce functionally active T regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53:786-793.
17. Zhang X, Jiao C, Jia Z, Ren X, Li X, Zhao X. Investigation of the role of mesenchymal stem cells on keratoplasty rejection. Chin J Ophthalmol 2012; 48:733-738.
18. Caspi RR. Experimental autoimmune uveoretinitis in the rat and mouse. Curr Protoc Immunol 2003; Chapter 15: Unit 15-16.
19. Shao H, Van Kaer L, Sun SL, Kaplan HJ, Sun D. Infiltration of the inflamed eye by NKT cells in a rat model of experimental autoimmune uveitis. J Autoimmun 2003; 21:37-45.
20. Amadi-Obi A, Yu CR, Liu X etal. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:711-718.
21. Chi W, Yang P, Li B etal. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 2007; 119:1218-1224.
22. Chi W, Zhu X, Yang P etal. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49:3058-3064.
23. Luger D, Silver PB, Tang J etal. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008; 205:799-810.
24. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 2010; 1183:211-221.
25. Horai R, Caspi RR. Cytokines in autoimmune uveitis. J Interferon Cytokine Res 2011; 31:733-744.
26. Ke Y, Jiang G, Sun D, Kaplan HJ, Shao H. Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest Ophthalmol Vis Sci 2008; 49:3999-4007.
27. Sun M, Yang P, Du L, Zhou H, Ren X, Kijlstra A. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2010; 51:383-389.
28. Chen L, Yang P, Zhou H etal. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci 2008; 49:3475-3482.
29. Bettelli E, Carrier Y, Gao W etal. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238.
30. Zhou L, Lopes JE, Chong MM etal. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453:236-240.
31. Korn T, Mitsdoerffer M, Croxford AL etal. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008; 105:18460-18465.
32. Ferraro A, Socci C, Stabilini A etal. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011; 60:2903-2913.
33. Niu Q, Cai B, Huang ZC, Shi YY, Wang LL. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012; 32:2731-2736.
34. Khoury SJ. Th17 and Treg balance in systemic sclerosis. Clin Immunol 2011; 139:231-232.
35. Batsali AK, Kastrinaki MC, Papadaki HA, Pontikoglou C. Mesenchymal stem cells derived from Wharton's jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther 2013; 8:144-155.